SCYNEXIS, Inc. (SCYX) News

SCYNEXIS, Inc. (SCYX): $1.60

0.03 (+1.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SCYX News Items

SCYX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SCYX News From Around the Web

Below are the latest news stories about SCYNEXIS INC that investors may wish to consider to help them evaluate SCYX as an investment opportunity.

SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. Approval is based on pivotal Phase 3 CANDLE data demonstrating statistically significant superiority of ibrexafungerp over placebo for primary and key secondary endpoints. JERSEY CITY, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative me

Yahoo | December 1, 2022

SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an “urgent threat” by the Centers for Disease Control (CDC) and included in the “critital priority group” on the World Health Organization (WHO) fungal priority pathogens list (FPPL). SCY-247 is a broad-spectrum, oral and IV antifungal under development by SCYNEXIS as a potential systemic therapeutic option for multiple drug-resistant pathogens. JERSEY CITY, N.J., Nov. 30, 2022

Yahoo | November 30, 2022

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus species.Ibrexafungerp, a first-in-class, broad-spectrum oral/IV antifungal meets all the priorities outlined by BARDA in its new Broad Agency Announcement (BAA) released this week, and has shown activity against multiple drug-resistant pathogens, including C. auris, C. albicans, C. glabrata, C. para

Yahoo | November 17, 2022

SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations

SCYNEXIS ( NASDAQ:SCYX ) Third Quarter 2022 Results Key Financial Results Net loss: US$29.6m (loss widened by US$29.0m...

Yahoo | November 11, 2022

Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on SCYNEXIS (SCYX)

E ratio of -1.13.

Christine Brown on TipRanks | November 10, 2022

Analysts’ Top Healthcare Picks: Larimar Therapeutics (LRMR), SCYNEXIS (SCYX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and SCYNEXIS (SCYX – Research Report) with bullish sentiments. Larimar Therapeutics (LRMR) JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Larimar Therapeutics today and set a price target of $16.00. The company's shares closed last Thursday at $3.07, close to its 52-week low of $1.53. According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -38.9% and a 14.0% success rate.

Christine Brown on TipRanks | November 10, 2022

Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer

Yahoo | November 9, 2022

SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi

Ibrexafungerp demonstrates activity against deadly fungal pathogens included in the World Health Organization’s (WHO) first fungal pathogens priority listJERSEY CITY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced the publication of a review article highlighting the potential use of ibrexafungerp as a novel treatment opti

Yahoo | November 7, 2022

Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001). In the pooled analysis, patients receiving ibrexafungerp experienced significantly higher rates of clinical improvement, complete symptom resolution, and mycological cure compared to placebo (all p < 0.0001). Ibrexafungerp demonstrated consistent efficacy in important patient sub-populations, characterized by race, body mass index, symptom severity, and

Yahoo | November 3, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.812 seconds.